Author:
Dal Pan Gerald J.,Raine June,Uzu Shinobu
Reference47 articles.
1. Flexibility in the FDA approach to orphan drug development
2. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
3. Ministry of Health Labour and Welfare.Overview of orphan drug/medical device designation system.2009.http://www.mhlw.go.jp/english/policy/health‐medical/pharmaceuticals/orphan_drug.html(accessed 19 December 2017)
4. European Medicines Agency.Orphan designation.2015.http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240ce&jsenabled=true(accessed 9 December 2017).